why choose us

First received: May 19, 2023

Clinical Trial: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Duchenne Muscular Dystrophy

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP- 9001 in Non-Ambulatory and Ambulatory Subjects W

Brief Summary: The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD.This is a randomized, double-blind, placebo-controlled 2-part study.Participants will be in the study for approximately 128 weeks.All participants will have the opportunity to receive intravenous (IV) delandistrogene moxeparvovec in either Part 1 or Part 2.

Read more